PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
22044398-0	2011	Effect of guaifenesin on mucin production, rheology, and mucociliary transport in differentiated human airway epithelial cells.	Guaifenesin	10-21	LOC100508689	Homo sapiens	25-30
23471625-0	2013	Characterization of the binding of metoprolol tartrate and guaifenesin drugs to human serum albumin and human hemoglobin proteins by fluorescence and circular dichroism spectroscopy.	Guaifenesin	59-70	albumin	Homo sapiens	92-99
23471625-1	2013	The interactions of metoprolol tartrate (MPT) and guaifenesin (GF) drugs with human serum albumin (HSA) and human hemoglobin (HMG) proteins at pH 7.4 were studied by fluorescence and circular dichroism (CD) spectroscopy.	Guaifenesin	50-61	albumin	Homo sapiens	90-97
23471625-1	2013	The interactions of metoprolol tartrate (MPT) and guaifenesin (GF) drugs with human serum albumin (HSA) and human hemoglobin (HMG) proteins at pH 7.4 were studied by fluorescence and circular dichroism (CD) spectroscopy.	Guaifenesin	63-65	albumin	Homo sapiens	90-97
22044398-3	2011	The authors hypothesized that guaifenesin improves mucociliary clearance in humans by reducing mucin release, by decreasing mucus viscoelasticity, and by increasing mucociliary transport.	Guaifenesin	30-41	LOC100508689	Homo sapiens	95-100
22044398-8	2011	Guaifenesin suppressed mucin production in a dose-dependent manner at clinically relevant concentrations.	Guaifenesin	0-11	LOC100508689	Homo sapiens	23-28
21184665-0	2010	Blockade of MUC1 expression by glycerol guaiacolate inhibits proliferation of human breast cancer cells.	Guaifenesin	31-51	mucin 1, cell surface associated	Homo sapiens	12-16
21184665-7	2010	Our results demonstrate that glycerol guaiacolate inhibits MUC1 protein and mRNA expression levels and significantly increased p21 expression in human breast cancer cells as well as induced PARP cleavage.	Guaifenesin	29-49	mucin 1, cell surface associated	Homo sapiens	59-63
21184665-7	2010	Our results demonstrate that glycerol guaiacolate inhibits MUC1 protein and mRNA expression levels and significantly increased p21 expression in human breast cancer cells as well as induced PARP cleavage.	Guaifenesin	29-49	H3 histone pseudogene 16	Homo sapiens	127-130
21184665-7	2010	Our results demonstrate that glycerol guaiacolate inhibits MUC1 protein and mRNA expression levels and significantly increased p21 expression in human breast cancer cells as well as induced PARP cleavage.	Guaifenesin	29-49	poly(ADP-ribose) polymerase 1	Homo sapiens	190-194
21184665-8	2010	Similarly, glycerol guaiacolate inhibited breast tumor growth in vivo as well as enhanced p21 expression and decreased breast tumor cell proliferation (ki-67 expression).	Guaifenesin	11-31	H3 histone pseudogene 16	Homo sapiens	90-93
21184665-9	2010	Collectively, our results demonstrate that glycerol guaiacolate decreased MUC1 expression and enhanced cell growth inhibition by inducing p21 expression in breast cancer cells.	Guaifenesin	43-63	mucin 1, cell surface associated	Homo sapiens	74-78
21184665-9	2010	Collectively, our results demonstrate that glycerol guaiacolate decreased MUC1 expression and enhanced cell growth inhibition by inducing p21 expression in breast cancer cells.	Guaifenesin	43-63	H3 histone pseudogene 16	Homo sapiens	138-141
15907635-1	2005	The electrochemical oxidation of Guaifenesin in a pharmaceutical formulation containing Guaifenesin has been carried out in Britton-Robinson buffer (BRB) (0.04 mol L-1) on platinum electrode.	Guaifenesin	33-44	L1 cell adhesion molecule	Mus musculus	164-167
18535166-6	2008	Patients (56/92) treated with the single agent guaifenesin (>3 months) had higher levels of eotaxin than those not treated (P<0.01).	Guaifenesin	47-58	C-C motif chemokine ligand 11	Homo sapiens	95-102
15907635-4	2005	A method for the analysis of Guaifenesin in BRB (0.04 mol L-1, pH 2), which allows quantification over the range 20-60 microg mL-1, was proposed and successfully applied to the determination of Guaifenesin in syrup with mean recovery and relative standard deviation of 103.3% and 1.32%, respectively.	Guaifenesin	29-40	L1 cell adhesion molecule	Mus musculus	58-61
15907635-4	2005	A method for the analysis of Guaifenesin in BRB (0.04 mol L-1, pH 2), which allows quantification over the range 20-60 microg mL-1, was proposed and successfully applied to the determination of Guaifenesin in syrup with mean recovery and relative standard deviation of 103.3% and 1.32%, respectively.	Guaifenesin	29-40	L1 cell adhesion molecule	Mus musculus	126-130
15907635-4	2005	A method for the analysis of Guaifenesin in BRB (0.04 mol L-1, pH 2), which allows quantification over the range 20-60 microg mL-1, was proposed and successfully applied to the determination of Guaifenesin in syrup with mean recovery and relative standard deviation of 103.3% and 1.32%, respectively.	Guaifenesin	194-205	L1 cell adhesion molecule	Mus musculus	126-130
30276968-7	2019	Functional heterologous expression of TAS2R14, a broadly tuned bitter taste receptor responding to guaifenesin, and experiments using these prodrugs revealed that, while some of the prodrugs still activated the receptor similarly or even stronger than the parent substance, succinate derivatization resulted in the complete loss of receptor responses.	Guaifenesin	99-110	taste 2 receptor member 14	Homo sapiens	38-45
7430296-4	1980	The detection limit for guaifenesin was 15 ng ml-1 for a 2.0-ml plasma sample.	Guaifenesin	24-35	interleukin 17F	Homo sapiens	46-50
5142865-0	1971	[Animal experiment on the absorption, distribution and elimination of C 14 - and H 3 -labelled guaiacol-glyceryl-ether].	Guaifenesin	95-118	H3 clustered histone 14	Homo sapiens	70-84
30276968-8	2019	The predicted binding modes of guaifenesin and its prodrugs to the TAS2R14 homology model suggest that the decreased activity of the succinate derivatives may be caused by a clash with Phe247.	Guaifenesin	31-42	taste 2 receptor member 14	Homo sapiens	67-74
26763117-5	2016	Nine exercised Thoroughbred horses were administered 2 g of guaifenesin orally BID for a total of five doses.	Guaifenesin	60-71	BH3 interacting domain death agonist	Equus caballus	79-82
28356767-8	2017	Treatment with guaifenesin 1200 mg BID provided 25% greater reduction in mean muscle spasm over its matched placebo and 16% greater reduction than guaifenesin 600 mg BID.	Guaifenesin	15-26	BH3 interacting domain death agonist	Homo sapiens	35-38
28356767-12	2017	CONCLUSION: Results suggest the potential for OTC dose of guaifenesin 1200 mg BID to provide symptomatic relief of upper back musculoskeletal pain and spasm.	Guaifenesin	58-69	BH3 interacting domain death agonist	Homo sapiens	78-81